NCT02273388View on ClinicalTrials.gov

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 4, 2005

Primary Completion Date

January 19, 2009

Study Completion Date

April 6, 2021

Conditions
Neoplasms
Interventions
DRUG

BI 6727

BI 6727

Trial Locations (2)

Unknown

1230.1.32002 Boehringer Ingelheim Investigational Site, Brussels

1230.1.32001 Boehringer Ingelheim Investigational Site, Leuven

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY